Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

Inclusion Criteria:

* Males and females 18 to 65 years old inclusive
* MM patients with clinically significant disease that achieved at least Partial Response (PR) after induction chemotherapy
* Patients eligible for HDC with PBSC support.
* Patients who require stem cell collection with CTX and G-CSF priming.
* Normal LV functions (EF over 50%, DLCO over 50%)
* Karnofsky score \> 60%,
* Patients must have normal renal and liver functions as defined below:

  * Total bilirubin ≤2.0 x institutional upper limit of normal (ULN), unless the patient has a known diagnosis of Gilbert's disease.
  * Aspartate transaminase (AST, SGOT) or alanine transaminase (ALT, SGPT) ≤3 x institutional ULN.
  * Serum creatinine ≤1.5 g/dL or calculated estimated creatinine clearance ≥40 mL/min
* Polymorphonuclear neutrophil (PMN) count \> 1,500
* PLT \>100,000
* Hemoglobin \> 9gr%
* Women of child-bearing potential must have a negative serum or urine pregnancy test at enrollment.
* If female, the patient is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (e.g., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide or abstinence) from the enrollment visit through 30 days after the administration of the study drug.
* If male, the patient agrees to use an acceptable barrier method of contraception from the time of enrollment through 30 days after the administration of the study drug.
* Prior to enrollment, the patient is capable of understanding the protocol and able to sign a written informed consent.

Exclusion Criteria:

* Patients who have not achieved at least Partial Response (PR) following induction chemotherapy.
* No pervious G-CSF therapy.
* Creatinine clearance \<40 mL /min.
* Body temperature above 385 C on day 10.
* Patients with blood pressure \<105/60
* Any of the following in the last 3 months prior to enrollment: Unstable Angina, Acute Myocardial Infarction (MI), Congestive Heart Failure, CVA, uncontrolled blood pressure
* Pregnant or breast-feeding women.
* Any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.
* Treatment with any investigational agents in the last 21 days before study entry.
* Any condition or circumstance which, in the opinion of the Investigator, would significantly interfere with the patient's protocol compliance and put the patient at increased risk.